Microfluidics: a transformational tool for nanomedicine development and production
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Microfluidic devices are mircoscale fluidic circuits used to manipulate liquids at the nanoliter scale. The ability to control the mixing of fluids and the continuous nature of the process make it apt for solvent/antisolvent precipitation of drug-delivery nanoparticles. This review describes the use of numerous microfluidic designs for the formulation and production of lipid nanoparticles, liposomes and polymer nanoparticles to encapsulate and deliver small molecule or genetic payloads. The advantages of microfluidics are illustrated through examples from literature comparing conventional processes such as beaker and T-tube mixing to microfluidic approaches. Particular emphasis is placed on examples of microfluidic nanoparticle formulations that have been tested in vitro and in vivo. Fine control of process parameters afforded by microfluidics, allows unprecedented optimization of nanoparticle quality and encapsulation efficiency. Automation improves the reproducibility and optimization of formulations. Furthermore, the continuous nature of the microfluidic process is inherently scalable, allowing optimization at low volumes, which is advantageous with scarce or costly materials, as well as scale-up through process parallelization. Given these advantages, microfluidics is poised to become the new paradigm for nanomedicine formulation and production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · cited 1×
“taining lipid nanoparticles (LNPs) [14,15], liposomes [16,17] and”
BackgroundDiffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“since the mid-1960s when liposomes were first utilized as carriers for proteins and drugs [12,13].”
BackgroundKnocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“LNPs containing DLin-KC2-DMA have demonstrated increased potency of in vivo gene silencing in a factor VII model, while DLin-MC3-DMA-based LNPs have been used successfully in clinical studies (ALN-TTR02, ALN-PCS) [4,6,33,34].”
MethodRNAi-mediated gene silencing in non-human primates
Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., et al. (2006) · Nature · doi:10.1038/nature04688 · Cited by 1,357 · cited 2×
“were able to reduce the particle size to around 80 nm and increase the encapsulation to about 95% by using a higher concentration of cationic lipid and lower concentration of DSPC, which, respectively, were believed to increase interaction with siRNA and favor smaller electron-dense nanostructures [32,38].”
BackgroundMethodMicrofluidic Platform for Controlled Synthesis of Polymeric Nanoparticles
Karnik, R., Gu, F., Basto, P., Cannizzaro, C., Dean, L., Kyei-Manu, W., Langer, R., & Farokhzad, O. C. (2008) · Nano Letters · doi:10.1021/nl801736q · Cited by 887
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., et al. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.28 · Cited by 685 · cited 6×
“Previous studies have reported a change in size from 25–100 nm solely by modifying the PEG-lipid content from 1–5 mol% (Figure 2(c)) [35].”
BackgroundInfluentialMaier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625 · cited 1×
“LNPs containing DLin-KC2-DMA have demonstrated increased potency of in vivo gene silencing in a factor VII model, while DLin-MC3-DMA-based LNPs have been used successfully in clinical studies (ALN-TTR02, ALN-PCS) [4,6,33,34].”
MethodCationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Liposomes for use in gene delivery
Balazs, D. A., & Godbey, W. (2011) · Journal of Drug Delivery · doi:10.1155/2011/326497 · Cited by 441
Cited by
Liposomes: Advancements and innovation in the manufacturing process
Shah, S., Dhawan, V., Holm, R., Nagarsenker, M. S., & Perrie, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.002 · Cited by 745
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 592
Solid Lipid Nanoparticles vs. Nanostructured Lipid Carriers: A Comparative Review
Viegas, C., Patrício, A. B., Prata, J. M., Nadhman, A., Chintamaneni, P. K., & Fonte, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061593 · Cited by 524
Nanostructured Lipid Carriers for Delivery of Chemotherapeutics: A Review
Haider, M., Abdin, S. M., Kamal, L., & Orive, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030288 · Cited by 451
Microfluidic formulation of nanoparticles for biomedical applications
Shepherd, S. J., Issadore, D., & Mitchell, M. J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120826 · Cited by 433
Metadata
- Authors
- Garg, S., Heuck, G., Ip, S., & Ramsay, E.
- Venue
- Journal of Drug Targeting
- Publisher
- Informa UK Limited
- Published
- 2016-08-05
- Volume
- 24
- Issue
- 9
- Pages
- 821-835
- ISSN
- 1026-7158 (ISSN-L)
- 1061-186X
- 1029-2330
- OpenAlex
- W2495910706
- Cited by
- 72
- References
- 16
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microfluidics: a transformational tool for nanomedicine development and production. https://app.cochat.ai/papers/10.1080/1061186x.2016.1198354
- The paper
- Garg, S., Heuck, G., Ip, S., & Ramsay, E. (2016). Microfluidics: a transformational tool for nanomedicine development and production. Journal of Drug Targeting. https://doi.org/10.1080/1061186x.2016.1198354
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.